212 related articles for article (PubMed ID: 23233277)
1. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.
Inancli SS; Usluogullari A; Ustu Y; Caner S; Tam AA; Ersoy R; Cakir B
Endocrine; 2013 Aug; 44(1):193-9. PubMed ID: 23233277
[TBL] [Abstract][Full Text] [Related]
2. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
Ciresi A; Amato MC; Guarnotta V; Lo Castro F; Giordano C
Clin Endocrinol (Oxf); 2013 Dec; 79(6):845-52. PubMed ID: 23506485
[TBL] [Abstract][Full Text] [Related]
3. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
Pirchio R; Auriemma RS; Solari D; Arnesi M; Pivonello C; Negri M; de Angelis C; Cavallo LM; Cappabianca P; Colao A; Pivonello R
Front Endocrinol (Lausanne); 2021; 12():769744. PubMed ID: 34917030
[TBL] [Abstract][Full Text] [Related]
4. Metabolic syndrome associated with hyperprolactinemia: a new indication for dopamine agonist treatment?
Bernabeu I; Casanueva FF
Endocrine; 2013 Oct; 44(2):273-4. PubMed ID: 23975607
[No Abstract] [Full Text] [Related]
5. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma.
Doğan BA; Arduç A; Tuna MM; Nasıroğlu NI; Işık S; Berker D; Güler S
Anatol J Cardiol; 2016 Jun; 16(6):440-7. PubMed ID: 26680550
[TBL] [Abstract][Full Text] [Related]
7. Mean platelet volume in patients with prolactinoma.
Tam AA; Kaya C; Başer H; Ersoy R; Çakır B
Arch Endocrinol Metab; 2016 Aug; 60(4):319-22. PubMed ID: 26886093
[TBL] [Abstract][Full Text] [Related]
8. Prolactinoma - which patients react favorably to cabergoline medication?
Karatas S; Hacioglu Y; Rakicioglu T
Endocr Regul; 2022 Oct; 56(4):279-283. PubMed ID: 36270341
[No Abstract] [Full Text] [Related]
9. Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study.
Jiang XB; Li CL; He DS; Mao ZG; Liu DH; Fan X; Hu B; Zhu YH; Wang HJ
Pituitary; 2014 Jun; 17(3):232-9. PubMed ID: 23756783
[TBL] [Abstract][Full Text] [Related]
10. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
11. SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA.
Arslan MS; Sahin M; Karakose M; Tutal E; Topaloglu O; Ucan B; Demirci T; Caliskan M; Ozdemir S; Ozbek M; Cakal E
Endocr Pract; 2017 Mar; 23(3):266-370. PubMed ID: 27849387
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
13. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
14. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study.
Posawetz AS; Trummer C; Pandis M; Aberer F; Pieber TR; Obermayer-Pietsch B; Pilz S; Theiler-Schwetz V
BMC Endocr Disord; 2021 Apr; 21(1):81. PubMed ID: 33902531
[TBL] [Abstract][Full Text] [Related]
15. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
Krysiak R; Okopien B
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
[TBL] [Abstract][Full Text] [Related]
16. Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration.
Melis GB; Gambacciani M; Paoletti AM; Mais V; Sghedoni D; Fioretti P
Fertil Steril; 1989 Sep; 52(3):412-5. PubMed ID: 2570719
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.
Cho EH; Lee SA; Chung JY; Koh EH; Cho YH; Kim JH; Kim CJ; Kim MS
J Korean Med Sci; 2009 Oct; 24(5):874-8. PubMed ID: 19794986
[TBL] [Abstract][Full Text] [Related]
18. Metabolic effects of dopamine-agonists treatment among patients with prolactinomas.
Kabootari M; Shirmohammadli H; Golgiri F; Mosalamiaghili S; Khajavi A; Akbari H
Endocrine; 2023 Mar; 79(3):537-544. PubMed ID: 36352337
[TBL] [Abstract][Full Text] [Related]
19. [Serum concentrations of glucose, cholesterol and triglycerides in men with prolactinoma treated with cabergoline].
Iglesias P; Villabona C; Díez JJ
Med Clin (Barc); 2016 Nov; 147(10):466-467. PubMed ID: 27452305
[No Abstract] [Full Text] [Related]
20. Effect of cabergoline on metabolism in prolactinomas.
Auriemma RS; Granieri L; Galdiero M; Simeoli C; Perone Y; Vitale P; Pivonello C; Negri M; Mannarino T; Giordano C; Gasperi M; Colao A; Pivonello R
Neuroendocrinology; 2013; 98(4):299-310. PubMed ID: 24355865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
